FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Premier Roadlines IPO and Quest Laboratories IPO.
Premier Roadlines IPO is a SME Book Built Issue IPO proposed to list at NSE SME while Quest Laboratories IPO is a SME Book Built Issue proposed to list at NSE SME.
Premier Roadlines IPO | Quest Laboratories IPO | |
---|---|---|
Logo | ||
Issue Category | SME | SME |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Book Built Issue |
Listing At | NSE SME | NSE SME |
Lead Managers | Hem Securities Limited | Shreni Shares Limited |
Registrar | Maashitla Securities Private Limited | Bigshare Services Pvt Ltd |
Market Maker | Hem Finlease Private Limited | Rikhav Securities Limited |
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | Anchor Investor | Anchor Investor |
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Premier Roadlines IPO is up to ₹40.36 Cr whereas the issue size of the Quest Laboratories IPO is up to ₹43.16 Cr. The final issue price of Premier Roadlines IPO is ₹67.00 per share and of Quest Laboratories IPO is ₹97.00 per share.
Premier Roadlines IPO | Quest Laboratories IPO | |
---|---|---|
Face Value | ₹10 per share | ₹10 per share |
Issue Price (Lower) | ₹63.00 per share | ₹93.00 per share |
Issue Price (Upper) | ₹67.00 per share | ₹97.00 per share |
Issue Price (Final) | ₹67.00 per share | ₹97.00 per share |
Discount (Retail) | ||
Discount (Employee) | ||
Market Lot Size | 2000 shares | 1200 shares |
Fresh Issue Size | 60,24,000 shares | 44,49,600 shares |
Fresh Issue Size (Amount) | up to ₹40.36 Cr | up to ₹43.16 Cr |
OFS Issue Size | ||
OFS Issue Size (Amount) | ||
Issue Size Total | 60,24,000 shares | 44,49,600 shares |
Issue Size Total (Amount) | up to ₹40.36 Cr | up to ₹43.16 Cr |
Premier Roadlines IPO opens on May 10, 2024, while Quest Laboratories IPO opens on May 15, 2024. The closing date of Premier Roadlines IPO and Quest Laboratories IPO is May 14, 2024, and May 17, 2024, respectively.
Premier Roadlines IPO | Quest Laboratories IPO | |
---|---|---|
Anchor Bid Date | May 09, 2024 | May 14, 2024 |
Issue Open | May 10, 2024 | May 15, 2024 |
Issue Close | May 14, 2024 | May 17, 2024 |
Basis Of Allotment (Tentative) | May 15, 2024 | May 21, 2024 |
Initiation of Refunds (Tentative) | May 16, 2024 | May 22, 2024 |
Credit of Share (Tentative) | May 16, 2024 | May 22, 2024 |
Listing date (Tentative) | May 17, 2024 | May 23, 2024 |
Anchor Lockin End date 1 | Jun 14, 2024 | Jun 20, 2024 |
Anchor Lockin End date 2 | Aug 13, 2024 | Aug 19, 2024 |
Premier Roadlines IPO P/E ratio is 15.7, as compared to Quest Laboratories IPO P/E ratio of 23.03.
Premier Roadlines IPO | Quest Laboratories IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial | Premier Roadlines Limited Financial Information (Restated Standalone)
|
Quest Laboratories Limited Financial Information (Restated)Quest Laboratories Limited's revenue increased by 3.9% and profit after tax (PAT) rose by 22.5% between the financial year ending with March 31, 2023 and March 31, 2022.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 100.00% | 90.36% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 73.65% | 65.82% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | 15.7 | 23.03 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ₹153.18 Cr. | ₹158.96 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROE | 27.85%% | 34.03%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROCE | 20.05%% | 41.86%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | 1.04 | 0.2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPS | ₹4.27 | ₹4.21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RoNW | 24.45%% | 34.03%% |
In the Premier Roadlines IPO retail investors (RII) are offered 20,04,000 shares while in Quest Laboratories IPO retail investors are offered 20,04,000 shares. Qualified institutional buyers (QIB) are offered 11,44,000 shares in Premier Roadlines IPO and 8,31,600 shares in Quest Laboratories IPO.
Premier Roadlines IPO | Quest Laboratories IPO | |
---|---|---|
Anchor Investor Reserveration | 17,14,000 shares | 12,36,000 shares |
Market Maker Reserveration | 3,04,000 shares | 2,28,000 shares |
QIB | 11,44,000 shares | 8,31,600 shares |
NII | 8,58,000 shares | 6,55,200 shares |
RII | 20,04,000 shares | 14,98,800 shares |
Employee | 0 shares | 0 shares |
Others | ||
Total | 40,06,000 shares | 29,85,600 shares |
Premier Roadlines IPO subscribed 117.57x in total, whereas Quest Laboratories IPO subscribed 85.26x.
Premier Roadlines IPO | Quest Laboratories IPO | |
---|---|---|
QIB (times) | 89.95x | 57.20x |
NII (times) | 180.25x | 184.10x |
Big NII (times) | ||
Small NII (times) | ||
RII (times) | 106.50x | 57.63x |
Employee (times) | ||
Other (times) | ||
Total (times) | 117.57x | 85.26x |
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|